On the other hand, treatment of loiasis patients with reslizumab, an anti-IL-5 antibody, decreased absolute eosinophil counts in the peripheral blood, but had no effect on MF clearance nor did it lead to an improvement of adverse events suggesting that eosinophil depletion has less impact on post-DEC adverse events in loiasis patients than assumed (150). Here, IL5 is linked to loiasis.